A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer

PIK3CA mutation frequency varies among breast cancer (BC) subtypes. Recent evidence suggests combination therapy with the PI3K inhibitor (PI3Ki) alpelisib and endocrine therapy (ET) improves response rates and progression-free survival (PFS) in PIK3CA-mutant, hormone receptor positive (HR+) BC versu...

Full description

Saved in:
Bibliographic Details
Main Authors: Elizabeth J. Anderson, Lea E. Mollon, Joni L. Dean, Terri L. Warholak, Ayal Aizer, Emma A. Platt, Derek H. Tang, Lisa E. Davis
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:International Journal of Breast Cancer
Online Access:http://dx.doi.org/10.1155/2020/3759179
Tags: Add Tag
No Tags, Be the first to tag this record!